Asymmetrx
Country not established
- Devices
- 1
What Asymmetrx makes
Asymmetrx develops a diagnostic test for detecting prostate-specific antigen (PSA) mutations associated with aggressive prostate cancer, specifically targeting the TMPRSS2:ERG fusion variant.
The company’s diagnostic test is classified as Class I under FDA regulations and is listed via the 510(k) pathway. The portfolio is regulated in the United States.
Catalogue
Prostate-63 Cancer Diagnostic Test Ref K050063
510(k) 510(k)
Frequently asked questions
How many devices does Asymmetrx have in the registry?
The registry currently lists 1 device for Asymmetrx. Devices recorded under merged duplicate company entries are counted once.
Which registries list Asymmetrx's devices?
Among its 1 most recently registered device, Asymmetrx has devices listed in FDA 510(k) (1 device).
What risk classes do Asymmetrx's devices fall under?
Among its 1 most recently registered device, the classes recorded for Asymmetrx's devices are Class I. Each device page shows its own class and authorisation.
What are the newest devices from Asymmetrx in the registry?
The most recently registered devices listed for Asymmetrx include PROSTATE-63 CANCER DIAGNOSTIC TEST.